CD274 and digestive system neoplasm: These results indicate that anti-proteolytic PD-1/PD-L1 polypeptide inhibitors can be administered orally in the treatment of gastrointestinal tumors, which opens up new prospects for the development of oral drugs in tumor immunotherapy.